You are receiving this email because you are subscribed to Behind the Markets. If you no longer wish to receive these emails, please unsubscribe here.
Dear Fellow Investor,
Investors should always be on the lookout for insights that could give them an edge in the stock market, and one potential source of such information is insider buying activity. When company insiders, such as executives or board members, buy shares of a company’s stock, it can be seen as a vote of confidence in the company’s prospects. Publicly available insider buying information can provide valuable clues about which stocks may be worth considering for investment.
Here are three stocks recently purchased by C-level insiders –
Palmer Square Capital BDC Inc.– SYM: PSBD Recent Price: $16.31 Insider Action: 4 insiders buy $12 mil in shares Description: Palmer Square Capital BDC, Inc. engages in the provision of investment funds. It lends and invests in corporate debt securities of companies. The company was founded in 2019 and is headquartered in Mission Woods, KS.
===
U.S. Government Secretly Preparing for World War III This war could trigger the final collapse of the U.S. dollar, wiping out millions of Americans. The U.S. Treasury Department will be issuing a bunch of bonds this month. And that could trigger the final collapse of the purchasing power of the dollars in your wallet, your checking account, and your retirement savings account.
Most people will do nothing and could lose everything.
Erasca, Inc.– SYM: ERAS Recent Price: $1.72 Get Insider Action Here >>> Description: Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
===
10 Best Stocks to Own in 2024 Now, more than ever, value and yield are critical for successful investing. In 2024, focusing on value, opportunity, and dividends will be crucial due to the potential market correction.
That’s why we at Marketbeat have just released our list of the 10 Best Stocks to Own in 2024. This report is completely free, and the stocks revealed in it have the potential to change your income path.
Dominari Holdings Inc.– SYM: DOMH Recent Price: $2.07 Get Insider Action Here >>> Description: Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company’s pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.
